Diagnostic accuracy outcomes for virus tests
| Reference | Assay and target | Number of patients/samples | Index test; comparator (if applicable) |
| Pooled sensitivity | |||
| Updated analysis including results from Kim et al (2020) systematic review and meta-analysis and subsequent publications35 | NR | n=3818; 16 studies | RT-PCR: 87.8% (95% CI 81.5% to 92.2%) |
| Sensitivity for studies that could not be pooled | |||
| Baek et al (2020)36 | N | n=154 samples | RT-LAMP: 100% |
| Harrington et al (2020)37 | RdRp | n=524 patients | Isothermal amplification (Abbott ID-NOW assay): 74.7% (95% CI 67.8% to 80.8%) |
| Lu et al (2020)38 | N | n=56 patients | RT-LAMP: 94.4% (95% CI 81.3% to 99.3%) |
| Yan et al (2020)39 | Orf1ab and spike | n=130 samples | RT-LAMP: 100% (95% CI 92.3% to 100%) |
| Zhen et al (2020)40 | N2, E | n=108 samples | RT-PCR (Cepheid Xpert Xpress SARS-CoV-2 assay): 98.3% (95% CI 90.7% to 99.9%) |
| RdRp | n=108 samples | Isothermal amplification (Abbott ID NOW COVID-19 assay): 87.7% (95% CI 76.3% to 94.9%) | |
| NR | n=108 samples | DNA hybridisation and electrochemical detection (GenMark ePlex): 98.3% (95% CI 90.7% to 99.9%) | |
| Specificity | |||
| Baek et al (2020)36 | N | n=154 samples | RT-LAMP: 98.7% |
| Lu et al (2020)38 | N | n=56 patients | RT-LAMP: 90.0% (95% CI 68.3% to 98.8%) |
| Harrington et al (2020)37 | RdRp | n=524 patients | Isothermal amplification (Abbott ID-NOW assay): 99.4% (95% CI 97.8% to 99.9%) |
| Yan et al (2020)39 | Orf1ab and spike | n=130 specimens | RT-LAMP: 100% (95% CI 93.7% to 100%) |
| Zhen et al (2020)40 | N2, E | n=108 samples | RT-PCR (Cepheid Xpert Xpress SARS-CoV-2 assay): 98.3% (95% CI 92.3% to 100%) |
| RdRp | n=108 samples | Isothermal amplification (Abbott ID NOW COVID-19 assay): 87.7% (95% CI 92.3% to 100%) | |
| NR | n=108 samples | DNA hybridisation and electrochemical detection (GenMark ePlex): 100% (95% CI 92.3% to 100%) |
RT-LAMP, reverse transcription loop-mediated isothermal amplification; NR, details not reported.